US court invalidates one of two Gemzar patents
This article was originally published in Scrip
Executive Summary
A US district court has granted a motion filed by Sun Pharma for partial summary judgement in its three-year battle over Lilly's Gemzar (gemcitabine HCl for injection) – invalidating Lilly's method-of-use patent (the '826 patent), which includes paediatric exclusivity and is set to expire in May 2013.